Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$49.25

-0.76 (-1.52%)

, PFE

Pfizer

$32.64

-0.435 (-1.32%)

10:22
10/13/16
10/13
10:22
10/13/16
10:22

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) downgraded to Buy from Conviction Buy at Goldman with analyst Jami Rubin saying disappointing CM-26 data adds a greater level of uncertainty to future trials. 2. Pfizer (PFE) downgraded to Hold from Buy at Jefferies with analyst Jeffrey Holford citing a lack of positive catalysts. 3. Coach (COH) downgraded to Mixed from Positive at OTR Global citing checks that indicate less competitive offerings, reduced promotions, and feedback of some share loss by store managers. 4. E-Trade (ETFC) downgraded to Neutral from Buy at BofA/Merrill. 5. Deckers Brands (DECK) downgraded to Negative from Neutral at Susquehanna with analyst Sam Poser saying he believes the health of the UGG brand is clearly at risk as the company has already started promotional activity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

BMY

Bristol-Myers

$49.25

-0.76 (-1.52%)

PFE

Pfizer

$32.64

-0.435 (-1.32%)

COH

Coach

$35.67

-0.86 (-2.35%)

ETFC

E-Trade

$28.71

-0.22 (-0.76%)

DECK

Deckers Brands

$56.25

-4.73 (-7.76%)

  • 27

    Oct

  • 31

    Oct

  • 01

    Nov

  • 06

    Nov

  • 07

    Nov

BMY Bristol-Myers
$49.25

-0.76 (-1.52%)

09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
10/13/16
GSCO
10/13/16
DOWNGRADE
GSCO
Buy
Bristol-Myers downgraded to Buy from Conviction Buy at Goldman
Goldman analyst Jami Rubin removed Bristol-Myers from the Conviction Buy List and lowered its price target to $67 from $75 saying disappointing CM-26 data adds a greater level of uncertainty to future trials. He continues to believe is well positioned for 2017, and view the shares as very attractive over the long-term.
PFE Pfizer
$32.64

-0.435 (-1.32%)

09/14/16
BMOC
09/14/16
NO CHANGE
BMOC
Pfizer should exceed fiscal 2016 guidance, says BMO Capital
BMO Capital analyst Alex Arfaei says that Pfizer should exceed its fiscal 2016 guidance. The analyst says that Medivation, which Pfizer agreed to acquire, gives Pfizer another growth driver. Additionally, Pfizer has a number of other "high margin specialty drugs," according to the analyst. He says that the stock's dividend yield is "attractive," and he keeps a $40 price target and Outperform rating on the shares.
10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.
10/07/16
ROTH
10/07/16
NO CHANGE
Target $160
ROTH
Buy
ICU Medical price target raised to $160 from $132 at Roth Capital
Roth Capital analyst Chris Lewis raised his price target for ICU Medical (ICUI) to $160 from $132 after the company announced an agreement to acquire Hospira Infusion Systems from Pfizer (PFE) for $1B. The analyst is overall positive on the deal as it removes the long-standing customer concentration overhang and grows ICU Medical into a legitimate pure-play infusion therapy company with a complete product portfolio. The company also preannounced Q3 preliminary results above expectations, he notes. Lewis reiterates a Buy rating on ICU Medical's shares.
08/23/16
RHCO
08/23/16
DOWNGRADE
RHCO
Neutral
Medivation downgraded to Neutral from Buy at SunTrust
Medivation (MDVN) has agreed to be acquired by Pfizer (PFE) for $81.50 per share.
COH Coach
$35.67

-0.86 (-2.35%)

09/30/16
09/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN) initiated with a Buy at Guggenheim. 2. Wal-Mart (WMT) initiated with an Overweight at KeyBanc and a Buy at Guggenheim. 3. Harley-Davidson (HOG) initiated with a Hold at Jefferies. 4. Coach (COH) was initiated with a Buy at Guggenheim while the firm initiated Michael Kors (KORS) with a Neutral. 5. First Solar (FSLR) initiated with a Buy at Williams Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/04/16
WELS
10/04/16
NO CHANGE
WELS
Outperform
Coach still has upside as share retaken from Michael Kors, says Wells Fargo
Wells Fargo analyst Ike Boruchow believes that after Coach (COH) posted its first positive North American comp last quarter in over three years that it appears many investors have recently "moved on," viewing the turnaround story as played out. However, he thinks here is a long way to go should the brand continue to execute and finds it interesting that while investors were keenly aware of how much market share Michael Kors (KORS) was stealing over the past seven years, now it "doesn't seem like anyone is paying attention" as Coach finally takes back share at Kors' expense. Boruchow reiterate an Outperform rating and $46-$48 price target range on Coach share.
10/05/16
KEYB
10/05/16
DOWNGRADE
KEYB
Sector Weight
Vera Bradley downgraded to Sector Weight at KeyBanc
As previously reported, KeyBanc analyst Edward Yruma downgraded Vera Bradley (VRA) to Sector Weight from Overweight, as he sees risk to its earnings. Yruma thinks the brand's reboot has been successful, as reflected by the 20% year-over-year rise in shares, but with gross margins at their highest since 2010, sales need to increase to drive earnings, he tells investors. In the handbag space, Yruma prefers Coach (COH), on which he keeps an Overweight rating.
10/13/16
OTRG
10/13/16
DOWNGRADE
OTRG
Mixed
Coach downgraded to Mixed from Positive at OTR Global
OTR Global downgraded Coach to Mixed following checks that indicate less competitive offerings, reduced promotions, and feedback of some share loss by store managers.
ETFC E-Trade
$28.71

-0.22 (-0.76%)

09/30/16
SBSH
09/30/16
NO CHANGE
Target $31.5
SBSH
Neutral
Citi 'inclined to fade' September rally in TD Ameritrade
Citi analyst William Katz attributes the 5% September rally in shares of TD Ameritrade (AMTD) to speculation around a possible acquisition of E-Trade (ETFC). The rally in the shares likely discounts the earnings accretion from such a merger, Katz tells investors in a research note. He believes TD Ameritrade shares at current levels leave "no room for a bad outcome," which he defines as the company deciding not to pursue the deal or E-Trade acquiring Scottrade. As such, Katz says he's "inclined to fade the rally" in TD Ameritrade. The analyst has a Neutral rating on the shares with a $31.50 price target. TD Ameritrade is up 2% in early trading to $35.08.
09/30/16
WELS
09/30/16
NO CHANGE
WELS
Multiple companies could pursue Scottrade, says Wells Fargo
After Bloomberg reported that Scottrade is working with an adviser to explore selling itself, and the article mentioned Ameritrade (AMTD) as a potential suitor, Wells Fargo says that Charles Schwab (SCHW) and E-Trade (ETFC) could "also have interest" in Scottrade. The firm says that the deal could be accretive by double digit percentage levels for all of the potential suitors named. However, ti says that Ameritrade "may be the most logical buyer," since E-Trade just closed on an acquisition and Schwab has sought to place less emphasis trading. The firm keeps an Outperform rating on E-Trade and Market Perform ratings on Schwab and TD Ameritrade.
09/26/16
09/26/16
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Apache (APA) initiated with a Neutral at MUFG. 2. Marriott (MAR) was initiated with a Buy at Goldman while the firm initiated La Quinta (LQ) with a Sell. Goldman also initiated Red Rock Resorts (RRR), Hyatt (H), and Wyndham (WYN) with a Neutral. 3. Charles Schwab (SCHW) was initiated with an Overweight at Morgan Stanley while the firm initiated E-Trade (ETFC) and TD Ameritrade (AMTD) with an Equal Weight. 4. Valvoline (VVV) initiated with a Buy at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/13/16
BOFA
10/13/16
DOWNGRADE
Target $33
BOFA
Neutral
E-Trade downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Michael Carrier downgraded E-Trade to Neutral and raised its price target to $33 from $31.
DECK Deckers Brands
$56.25

-4.73 (-7.76%)

10/13/16
SUSQ
10/13/16
DOWNGRADE
Target $49
SUSQ
Negative
Deckers Brands downgraded to Negative at Susquehanna
As reported previously, Susquehanna analyst Sam Poser downgraded Deckers Brands to Negative from Neutral as he believes the health of the UGG brand is clearly at risk as the company has already started promotional activity. The analyst also reduced his estimates and believes gross margin improvement will be below expectations. Poser lowered his price target to $49 from $59 on Deckers Brands shares.
09/30/16
GUGG
09/30/16
INITIATION
GUGG
Neutral
Deckers Brands initiated with a Neutral at Guggenheim
08/15/16
08/15/16
UPGRADE

Outperform
Deckers Brands upgraded to Outperform at Telsey Advisory
As previously reported, Telsey Advisory upgraded Deckers to Outperform from Market Perform and raised its price target to $78 from $68. Analyst Kelly Chen said Deck has become more than just a winter story, although she expects weather will not be as unfavorable as it was last year, as new management is implementing real and meaningful changes that can improve sales and profitability, and drive growth over the long term. Chen highlights new and compelling product innovation, a more advanced and disciplined approach to segmenting the product and the distribution, and taking a hard line on driving efficiencies across the organization by reducing unproductive SKUs, improving lead times and closing stores that are not meeting the company's targets.
08/15/16
TLSY
08/15/16
UPGRADE
TLSY
Outperform
Deckers Brands upgraded to Outperform from Market Perform at Telsey Advisory

TODAY'S FREE FLY STORIES

X

U.S. Steel

$37.49

1.54 (4.28%)

18:49
12/07/16
12/07
18:49
12/07/16
18:49
Periodicals
U.S. Steel CEO: Company may bring back 10,000 U.S. jobs, CNBC says »

U.S. Steel could bring…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNDA

Vanda

$15.40

-0.6 (-3.75%)

18:47
12/07/16
12/07
18:47
12/07/16
18:47
Hot Stocks
Vanda settles Fanapt patent litigation with Apotex »

Vanda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AE

Adams Resources

$42.31

-0.68 (-1.58%)

, SWN

Southwestern Energy

$12.37

-0.08 (-0.64%)

18:46
12/07/16
12/07
18:46
12/07/16
18:46
Hot Stocks
Adams Resources appoints Josh Anders as CFO »

Adams Resources &…

AE

Adams Resources

$42.31

-0.68 (-1.58%)

SWN

Southwestern Energy

$12.37

-0.08 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EZPW

EZCORP

$11.80

0.05 (0.43%)

18:42
12/07/16
12/07
18:42
12/07/16
18:42
Earnings
EZCORP reports Q4 EPS with items (31c), may not compare to consensus 6c »

EPS figure includes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

RICE

Rice Energy

$24.59

-0.16 (-0.65%)

18:33
12/07/16
12/07
18:33
12/07/16
18:33
Initiation
Rice Energy initiated  »

Rice Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$770.42

5.7 (0.75%)

18:30
12/07/16
12/07
18:30
12/07/16
18:30
Periodicals
Amazon spokesperson denies 2,000 grocery stores report, CNET says »

Following a report by the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICON

Iconix Brand

$9.26

0.14 (1.54%)

18:23
12/07/16
12/07
18:23
12/07/16
18:23
Hot Stocks
Iconix Brand reports employment termination of Chief Strategy Officer Blumberg »

Iconix Brand disclosed in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBYI

Puma Biotechnology

$39.80

-2 (-4.78%)

18:23
12/07/16
12/07
18:23
12/07/16
18:23
Hot Stocks
Puma Biotechnology 'pleased' to complete biomarker analysis of neratinib »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTK

Flotek

$11.10

-2.01 (-15.33%)

18:17
12/07/16
12/07
18:17
12/07/16
18:17
Hot Stocks
Flotek: Reviewing FourWorld Capital short report, remain confident in product »

Speaking earlier during…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PBYI

Puma Biotechnology

$39.80

-2 (-4.78%)

18:09
12/07/16
12/07
18:09
12/07/16
18:09
Hot Stocks
Puma Biotechnology 'pleased' with preliminary neratinib activity »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNM

PNM Resources

$32.05

0.45 (1.42%)

18:09
12/07/16
12/07
18:09
12/07/16
18:09
Hot Stocks
PNM Resources requests an electric rate increase of $99M in New Mexico »

PNM Resources' New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

BK

BNY Mellon

$48.55

0.56 (1.17%)

18:03
12/07/16
12/07
18:03
12/07/16
18:03
Periodicals
BNY Mellon outage led to certain Swift payment failures, WSJ reports »

Bank of New York Mellon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRD

Tailored Brands

$18.93

0.62 (3.39%)

17:52
12/07/16
12/07
17:52
12/07/16
17:52
Hot Stocks
Tailored Brands up 22% to $23.20 after Q3 results beat estimates »

The company also raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

FLXS

Flexsteel Industries

$59.12

2.92 (5.20%)

, UNH

UnitedHealth

$159.40

2.08 (1.32%)

17:50
12/07/16
12/07
17:50
12/07/16
17:50
Hot Stocks
Flexsteel names Eric Rangen chair of the board »

Flexsteel Industries…

FLXS

Flexsteel Industries

$59.12

2.92 (5.20%)

UNH

UnitedHealth

$159.40

2.08 (1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$52.10

1.53 (3.03%)

, UA

Under Armour

$27.03

1.62 (6.38%)

17:49
12/07/16
12/07
17:49
12/07/16
17:49
Periodicals
Nike losing market share to faster-growing rivals, Barron's reports »

Despite being down nearly…

NKE

Nike

$52.10

1.53 (3.03%)

UA

Under Armour

$27.03

1.62 (6.38%)

ADDYY

adidas

$76.96

1.225 (1.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Dec

T

AT&T

$40.45

1.1 (2.80%)

17:45
12/07/16
12/07
17:45
12/07/16
17:45
Conference/Events
AT&T management to meet with Jefferies »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

EFC

Ellington Financial

$16.30

0.2 (1.24%)

17:41
12/07/16
12/07
17:41
12/07/16
17:41
Hot Stocks
Ellington Financial reports estimated book value per share $19.80 as of Nov 30 »

Ellington Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LULU

lululemon

$59.84

2.6 (4.54%)

, HRB

H&R Block

$23.34

0.65 (2.86%)

17:39
12/07/16
12/07
17:39
12/07/16
17:39
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

LULU

lululemon

$59.84

2.6 (4.54%)

HRB

H&R Block

$23.34

0.65 (2.86%)

VYGR

Voyager Therapeutics

$13.73

-0.27 (-1.93%)

GLW

Corning

$24.58

0.59 (2.46%)

CMTL

Comtech

$12.75

0.77 (6.43%)

VRNT

Verint

$38.30

0.1 (0.26%)

UNFI

United Natural Foods

$49.09

0.43 (0.88%)

OLLI

Ollie's Bargain Outlet

$31.85

0.35 (1.11%)

MIND

Mitcham Industries

$3.73

0.04 (1.08%)

CASY

Casey's General Stores

$124.22

1.14 (0.93%)

OHRP

Ohr Pharmaceutical

$2.53

-0.075 (-2.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 08

    Dec

  • 08

    Dec

  • 13

    Dec

  • 15

    Dec

  • 09

    Jan

  • 09

    Jan

TLRD

Tailored Brands

$18.93

0.62 (3.39%)

17:38
12/07/16
12/07
17:38
12/07/16
17:38
Hot Stocks
Tailored Brands says making 'solid progress' on cost reduction initiatives »

"Our improved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TLRD

Tailored Brands

$18.93

0.62 (3.39%)

17:37
12/07/16
12/07
17:37
12/07/16
17:37
Hot Stocks
Tailored Brands says on track to achieve targeted $50M of cost savings in FY16 »

"We are on track to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TLRD

Tailored Brands

$18.93

0.62 (3.39%)

17:36
12/07/16
12/07
17:36
12/07/16
17:36
Hot Stocks
Tailored Brands reports Q3 Men's Wearhouse SSS up 0.1% »

Reports Q3: Jos. A. Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

VLKAY

Volkswagen

$28.94

0.895 (3.19%)

17:35
12/07/16
12/07
17:35
12/07/16
17:35
Periodicals
EU to take action against seven countries over emissions failings, Reuters says »

After the Volkswagen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

  • 10

    Jan

TLRD

Tailored Brands

$18.93

0.62 (3.39%)

17:33
12/07/16
12/07
17:33
12/07/16
17:33
Earnings
Tailored Brands revises FY16 adjusted EPS view to $1.70-$1.85 from $1.55-$1.85 »

FY16 consensus $1.70.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TLRD

Tailored Brands

$18.93

0.62 (3.39%)

17:31
12/07/16
12/07
17:31
12/07/16
17:31
Earnings
Tailored Brands reports Q3 adjusted EPS 68c, consensus 55c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

DAL

Delta Air Lines

$51.10

1.67 (3.38%)

17:23
12/07/16
12/07
17:23
12/07/16
17:23
Periodicals
Delta experiments with free meals in coach, Bloomberg says »

Delta is testing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.